Arbutus Biopharma Corporation (ABUS) Financial Statements
Arbutus Biopharma Corporation (ABUS) reported trailing twelve-month revenue of $181.7M (up 1078.8% year on year) and net income of $153.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$24.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABUSArbutus Biopharma CorporationFollow ABUS — free
—
Price chart with a free account
- Market cap
- 831.0M
- P/E TTM
- 5.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.5 | 15.0 | 23.3 | 1.5 | 10.7 | 5.9 | 6.0 | 6.9 | 11.0 | 39.0 | 18.1 | 6.2 | 14.1 | 181.7 | |
| Gross profit | 14.9 | 14.0 | — | — | — | — | — | 6.4 | 9.1 | 36.8 | 18.1 | — | 3.0 | — | |
| Research & development | 21.5 | 38.7 | 51.5 | 61.3 | 62.7 | 57.9 | 57.6 | 49.3 | 65.5 | 84.4 | 73.7 | 54.0 | 25.2 | 17.8 | |
| Operating income | -12.2 | -33.4 | -103.9 | -491.6 | -110.9 | -89.8 | -143.9 | -57.8 | -73.5 | -65.5 | -78.1 | -76.3 | -38.2 | 149.0 | |
| Pre-tax income | -14.1 | -38.8 | -78.9 | -489.2 | -108.7 | -61.3 | -166.4 | -63.7 | -76.2 | -65.0 | -72.8 | -69.9 | -33.5 | 153.1 | |
| Income tax | — | — | -16.2 | -105.0 | -24.3 | -4.3 | -12.7 | 0.0 | 0.0 | 4.4 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -14.1 | -38.8 | -62.7 | -384.2 | -84.4 | -57.1 | -153.7 | -63.7 | -76.2 | -69.5 | -72.8 | -69.9 | -33.5 | 153.1 | |
| Diluted EPS ($) | -0.92 | -1.80 | -1.34 | -7.24 | -1.56 | -1.21 | -2.89 | -1.00 | -0.83 | -0.46 | -0.44 | -0.38 | -0.17 | 0.79 | |
| Diluted shares (mn) | 15.3 | 21.6 | 45.5 | 53.1 | 54.7 | 55.3 | — | 75.8 | 106.2 | 150.9 | 166.0 | 185.6 | 191.6 | — |
USD millions · SEC XBRL
Arbutus Biopharma Corporation — questions
- What is Arbutus Biopharma Corporation's revenue?
- $181.7M over the twelve months to 2026-06-30, up 1078.8% year on year, from its 10-Q and 10-K filings.
- What is Arbutus Biopharma Corporation's net income?
- $153.1M over the twelve months to 2026-06-30.
- What is Arbutus Biopharma Corporation's free cash flow?
- -$24.6M over the twelve months to 2026-06-30.
- What are Arbutus Biopharma Corporation's diluted earnings per share?
- $0.79 over the twelve months to 2026-06-30.
Every figure on this page comes from Arbutus Biopharma Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.